综述丨冠状动脉药物洗脱支架内再狭窄的最新研究进展

摘  要

药物洗脱支架（DES）的诞生和不断优化已经大大提高了经皮冠状动脉介入治疗（PCI）的安全性和有效性，但随着病例复杂性的增加和DES的超适应证应用，术后再狭窄率正逐年上升。因此，当前DES时代下，支架内再狭窄（ISR）仍是临床上亟待解决的一大难题。本文将主要就DES置入后ISR发生发展的病理机制、组织病理学及治疗策略的最新研究成果及进展进行综述。

Abstract

The advent and subsequent iterations of drug-eluting stent（DES） technologies have significantly improved the safety and efficacy of percutaneous coronary interventions（PCI）.However，with the increasing complexity of cases and off-label use of DES，the restenosis rates with DES are rising year by year. Therefore，in-stent restenosis（ISR） in the current DES era is still a major clinical challenge that needs to be addressed. This paper mainly reviews the latest research findings and progress on the pathological mechanisms，histopathology and treatment strategies of ISR after DES implantation.

扫码下载全文

END

本文出自《中国介入心脏病学杂志》，转载请注明来源。